Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis
Jennifer Gao, Joyce Cheng, Tatiana M. Prowell, Erik Bloomquist, Shenghui Tang, Suparna Wedam, Melanie Royce, Danielle Krol, Christy Osgood, Gwynn Ison, Rajeshwari Sridhara, Richard Pazdur, Julia A. Beaver, Laleh Amiri‐Kordestani
Topics & Concepts
FulvestrantMetastatic breast cancerMedicineOncologyCyclin-dependent kinase 4Internal medicineHormone receptorCancerBreast cancerDrugFood and drug administrationHormoneCancer researchPharmacologyEstrogen receptorCell cycleCyclin-dependent kinase 2Advanced Breast Cancer TherapiesCancer Treatment and PharmacologyHER2/EGFR in Cancer Research